Manchester Financial Inc Immuno Gen, Inc. Transaction History

Manchester Financial Inc

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Jul 21, 2021	SELL	$5.79 - $8.6 $5,211 - $7,740	-900 Closed	0 $0
Q4 2019 Jan 17, 2020	BUY	$2.25 - $5.8 $2,025 - $5,220	900 New	900 $5,000
Q3 2019 Oct 09, 2019	SELL	$2.22 - $3.39 $1,998 - $3,051	-900 Closed	0 $0
Q2 2019 Jul 23, 2019	BUY	$1.8 - $3.3 $1,620 - $2,970	900 New	900 $2,000

1.41M

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

Get notified when there are updates to the investment portfolio of Manchester Financial Inc, based on Form 13F filings with the SEC.

Stay updated on Manchester Financial Inc with notifications on news.